(0.24%) 5 193.21 points
(0.17%) 38 920 points
(0.16%) 16 375 points
(-0.47%) $78.11
(0.41%) $2.20
(-0.36%) $2 322.90
(-0.20%) $27.56
(2.37%) $987.80
(-0.01%) $0.928
(0.44%) $10.87
(0.16%) $0.797
(0.11%) $91.45
0.88% $ 8.00
Live Chart Being Loaded With Signals
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications...
Stats | |
---|---|
Dzisiejszy wolumen | 4 231.00 |
Średni wolumen | 4 761.00 |
Kapitalizacja rynkowa | 9.71M |
EPS | $0 ( 2024-03-28 ) |
Następna data zysków | ( $-0.810 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.590 |
ATR14 | $0.103 (1.26%) |
Aeterna Zentaris Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
FDMT | 0.971 |
FTXG | 0.968 |
KIDS | 0.964 |
CTKB | 0.964 |
ACCD | 0.962 |
SANA | 0.961 |
UAL | 0.961 |
STKS | 0.961 |
VIAV | 0.96 |
FMHI | 0.959 |
10 Najbardziej negatywne korelacje | |
---|---|
MTRX | -0.957 |
XLRN | -0.944 |
ATRS | -0.942 |
GXII | -0.939 |
KSICU | -0.939 |
EACPU | -0.938 |
HERA | -0.938 |
MURFU | -0.937 |
HNRG | -0.936 |
ZING | -0.936 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Aeterna Zentaris Inc Finanse
Annual | 2023 |
Przychody: | $4.58M |
Zysk brutto: | $4.18M (91.31 %) |
EPS: | $-3.47 |
FY | 2023 |
Przychody: | $4.58M |
Zysk brutto: | $4.18M (91.31 %) |
EPS: | $-3.47 |
FY | 2022 |
Przychody: | $5.64M |
Zysk brutto: | $5.48M (97.22 %) |
EPS: | $-7.76 |
FY | 2021 |
Przychody: | $5.26M |
Zysk brutto: | $5.17M (98.29 %) |
EPS: | $-1.750 |
Financial Reports:
No articles found.
Aeterna Zentaris Inc
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej